A phase II trial of interleukin-2 in myelodysplastic syndromes.

Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R
Br J Haematol. 1998 101 (1): 205-7

PMID: 9576203 · DOI:10.1046/j.1365-2141.1998.00672.x

Patients with myelodysplastic syndromes (MDS) show a decrease in the number and function of natural killer (NK) cells, including lymphokine activated killer (LAK) cell activity. Interleukin-2 (IL-2) stimulates the proliferation and activity of these lymphocytes. Anecdotal clinical experience has shown haematological and cytogenetic improvement in myelodysplasia by low-dose IL-2 treatment. A total of 10 patients with MDS were treated with 1 million units of IL-2 subcutaneously daily for 12 weeks. Even though improvement in CD16+/CD56+ cell numbers was seen in a majority of the patients, the haematological status and transfusion requirements remained unchanged. There was minimal toxicity from this therapy.

MeSH Terms (13)

Adult Aged Aged, 80 and over CD56 Antigen Female Humans Interleukin-2 Killer Cells, Natural Lymphocyte Count Male Middle Aged Myelodysplastic Syndromes Receptors, IgG

Connections (1)

This publication is referenced by other Labnodes entities: